tradingkey.logo

Cytomx Announces Positive Interim Data From Phase 1 Dose Escalation Study Of Epcam Antibody Drug Conjugate (Cx-2051) Candidate In Patients With Advanced Colorectal Cancer (Crc)

ReutersMay 12, 2025 11:27 AM

- CytomX Therapeutics Inc CTMX.O:

  • CYTOMX ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 DOSE ESCALATION STUDY OF EPCAM ANTIBODY DRUG CONJUGATE (CX-2051) CANDIDATE IN PATIENTS WITH ADVANCED COLORECTAL CANCER (CRC)

  • CYTOMX THERAPEUTICS INC - PLANNING PHASE 2 STUDY INITIATION IN 1H 2026

  • CYTOMX THERAPEUTICS INC - CX-2051 HAS BEEN GENERALLY WELL TOLERATED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI